| Literature DB >> 29154758 |
Owen Carmichael1, Adam J Schwarz2, Christopher H Chatham3, David Scott4, Jessica A Turner5, Jaymin Upadhyay6, Alexandre Coimbra7, James A Goodman8, Richard Baumgartner9, Brett A English10, John W Apolzan11, Preetham Shankapal11, Keely R Hawkins11.
Abstract
Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29154758 PMCID： PMC5931333 DOI： 10.1016/j.drudis.2017.11.012
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851